MedPath

Reducing Pacemaker Implantation After TAVR With Modified Implantation Technique

Completed
Conditions
PM Implantation After TAVR
Interventions
Procedure: TAVR
Registration Number
NCT04734392
Lead Sponsor
University of Ulm
Brief Summary

Hypothesis of the study is that a modified and improved implantation protocol (regarding membranous septum length and implantation depth) will decrease the need for permanent pacemaker stimulation follow TAVR-procedures.

Detailed Description

Project objectives or hypothesis Hypothesis of the study is that a modified and improved implantation protocol (regarding membranous septum length and implantation depth) will decrease the need for permanent pacemaker stimulation following TAVR-procedures.

Patient profile and sample size The study cohort will comprise of patients referred to transcatheter aortic valve replacement. Patients will be prospectively and consecutively screened and enrolled at a tertiary high-volume center in Germany. TAVR will be performed according to a modified implantation technique regarding membranous septum length. Pacemaker rates will be analyzed and compared to a historical control. Taking into account a contemporary pacemaker rate of 15%, a reduction to 7% will require a sample size of 239 patients per group to achieve statistically significance (Chi-squared test, alpha 0.05, beta 0.80).

Regarding the prospective cohort, interims analysis will be performed after each 10 TAVR procedures. In case a signal towards worse outcomes with the modified implantation technique will be observed, the institutional safety and endpoint adjudication committee will stop further execution of the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • All patients referred to TAVR procedure due to severe aortic stenosis
Exclusion Criteria
  • PM-implantation before TAVR
  • Valve-in-valve procedures

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Cohort BTAVRProspective study cohort 2020 + 2021 (TAVR implantation according new IFU)
Primary Outcome Measures
NameTimeMethod
Pacemaker implantation rateDay 5 after TAVR

Primary endpoint

Secondary Outcome Measures
NameTimeMethod
Extent of paravalvular leakDay 5 after TAVR

Secondary endpoint

Number of patients alive30 days

Secondary endpoint

Trial Locations

Locations (1)

Ulm University

🇩🇪

Ulm, Germany

© Copyright 2025. All Rights Reserved by MedPath